Bacitracin A

Bacitracin A Uses, Dosage, Side Effects, Food Interaction and all others data.

Bacitracin A is a combination of at least 9 bacitracins. 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy.

Bacitracin A was granted FDA approval on 29 July 1948.

Bacitracin A is a mixture of polypeptides that prevent the formation of the bacterial cell wall and oxidatively cleave DNA. It has a short duration of action as it must be given every 3 to 4 hours topically. Bacitracin A is nephrotoxic when given intramuscularly and may lead to renal failure.

Bacitracin A
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Bacitracin A
Availability	Prescription only
Generic	Bacitracin
Bacitracin Other Names	Bacitracin, Bacitracin A, Bacitracina
Related Drugs	amoxicillin, doxycycline, ciprofloxacin, metronidazole, azithromycin, clindamycin
Type
Formula	C₆₆H₁₀₃N₁₇O₁₆S
Weight	Average: 1422.693 Monoisotopic: 1421.748941023
Protein binding	Data regarding the protein binding of bacitracin in humans is not readily available.
Groups	Approved, Vet approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Bacitracin A is a cyclic polypeptide antibiotic used to prevent wound infections, treat pneumonia and empyema in infants, and to treat skin and eye infections.

Bacitracin A is indicated in topical formulations for acute and chronic localized skin infections. Occasionally, it is also used intramuscularly for infantile streptococcal pneumonia and empyema. Bacitracin A is also formulated as an ointment with neomycin and polymyxin B for over the counter use. A bacitracin ointment formulated with neomycin and polymyxin B along with hydrocortisone is indicated for the treatment of corticosteroid responsive dermatoses with secondary infection.

Bacitracin A is also used to associated treatment for these conditions: Acne, Bacterial Infections of the Intestine, Empyema, Eye Infections, Infected Wound, Infection, Inflammatory Reaction caused by Acne, Ocular Inflammatory Disease, Pneumonia, Skin Ulcer, Corticosteroid-responsive dermatoses, Infection in minor cuts, scrapes, or burns, Wound site

How Bacitracin A works

Bacitracin A binds to a divalent metal ion such as Mn(II), Co(II), Ni(II), Cu(II), or Zn(II). These complexes bind C₅₅-isoprenyl pyrophosphate, preventing the hydrolysis of a lipid dolichol pyrophosphate, which finally inhibits cell wall synthesis. Bacitracin A metal complexes also bind and oxidatively cleave DNA.

Toxicity

The oral LD₅₀ of bacitracin in rats is >2000mg/kg.

Specific data regarding bacitracin overdoses is not readily available. An overdose of bacitracin may lead to nephrotoxicity and patients should be treated with supportive measures.

Food Interaction

No interactions found.

Bacitracin A Disease Interaction

Major: colitis, dehydration, renal dysfunction

Volume of Distribution

Data regarding the volume of distribution of bacitracin in humans is not readily available.

Elimination Route

Topical, ophthalmic, and oral formulations of bacitracin are poorly absorbed systemically. Intramuscular bacitracin is readily and completely absorbed.

Half Life

Data regarding the half life of bacitracin in humans is not readily available.

Clearance

Data regarding the clearance of bacitracin in humans has not been well studied. A study of 9 subjects in 1947 shows a renal clearance of 105-283mL/min with an average renal clearance of 159mL/min.